TCE to demonstrate significant γδ T cell expansion and activation, potentially offering an alternative to conventional ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...

Allogene Therapeutics, Inc.’s ALLO share price has surged by 5.28%, which has investors questioning if this is right time to ...

Century Therapeutics, Inc. (NASDAQ: IPSC) announced that its management team will host a live fireside chat on Tuesday, April 22, 2025, at 10:00 a.m. EDT to discuss ...

The trial will assess the therapy’s pharmacokinetics, pharmacodynamics and safety, as well as its impact on disease activity.

Kyverna Therapeutics, Inc.’s KYTX share price has surged by 6.52%, which has investors questioning if this is right time to sell.

CAR T-cell therapy showed encouraging efficacy and good safety in newly diagnosed Ph-positive ALL,” the researchers wrote.

ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta, with key trials like LOTIS-5 and LOTIS-7 shaping its future prospects. Financially, ADCT holds $274.3 ...

Inebilizumab-cdon is the first FDA-approved treatment for IgG4-related disease, targeting CD19+ B cells to reduce inflammation and fibrosis. The MITIGATE trial showed inebilizumab significantly ...